Stock Price & Analysis

Analysis and Insights

To determine whether it’s a good time to buy or sell DOCS stock, we need to analyze both technical and fundamental factors.

Technical Analysis:

Doximity's stock price has been experiencing a bearish trend recently, with significant resistance around the $73.66 mark (Fibonacci R1). The latest candlestick chart shows a potential reversal pattern, indicating a possible short-term upside.

Valuation Analysis:

Doximity currently has a P/E ratio of 34.35, which is lower than the average for the healthcare technology sector, typically around 40-50. This suggests that the stock might be undervalued compared to its peers.

Sentiment and Analyst Ratings:

Analyst sentiment is mixed. While some analysts have raised their price targets, others maintain a hold rating. The average target price is around $72.50, which is higher than the current price, suggesting potential upside.

Fundamental Analysis:

The company's recent earnings report was strong, with revenue and EBITDA exceeding expectations. This could mean the company is performing well fundamentally. However, the high short interest might indicate some skepticism in the market.

Conclusion:

Given the strong earnings report and positive analyst sentiment, DOCS stock might be a good buy for long-term investors. However, the technical indicators suggest short-term volatility, so it's important to consider your investment horizon and risk tolerance.

Doximity (DOCS) is predicted to reach a price range of $70 to $90 by 2025, driven by strong Q3 earnings and analyst upgrades. The stock has shown resilience with earnings beating expectations and raised guidance, supported by analyst price target increases to as high as $90. However, bearish options activity suggests caution, with a high put/call ratio indicating potential volatility.

The S1 support level for DOCS Stock is $60.78 ,The R1 resistant level for DOCS Stock is $69.91.

As of the end of day on 2025-03-14, the price of DOCS Stock was $63.4.

The target price for DOCS Stock according to analyst rating is 72.50, with the highest price target at 90.00 and the lowest at 53.00. Analysts have a Moderate Buy rating on DOCS Stock overall.

The market cap of DOCS is $11.9B.

DOCS may be overvalued based on high valuation multiples and bearish options activity. Its PE ratio of 50.35 and EV/EBITDA of 34.16 suggest a premium price. The stock has seen bearish options trading with a Put/Call Ratio of 6.93, indicating negative sentiment. While some analysts have raised targets, others remain cautious, leading to a moderate buy consensus. The stock's current price may not justify its growth prospects, making it potentially overvalued.

Doximity, Inc. provides a digital platform for United States (U.S) medical professionals. The Company's cloud-based platform provides tools to its members, which help them to collaborate with colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with medical news and research, and manage careers. The Company supports physicians in practice of medicine with mobile and clinical workflow tools, such as voice and video telehealth, secure messaging and digital faxing. The Company's platform offers marketing, hiring, and telehealth solutions. Its marketing solutions enable pharmaceutical and health system customers to get content, services, and peer connections to medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms. Its telehealth solutions consist of software tools that include voice and video dialers, designed to connect patients with care providers.

Doximity (DOCS) stock is predicted to reach $120 by 2030. Strong revenue growth, high EBITDA margins, and positive analyst sentiment drive this forecast. Analysts have raised price targets, with some as high as $90, indicating confidence in the company's future performance.

DOCS has a total of 977 employees.